Psychedelics: Once Stigmatized, Are Now the Newest Therapeutics on the Block for Mental Health
Finally, new therapeutic options are emerging for mental health diseases including depression, anxiety, pain, addiction, PTSD, and other behavioral health disorders which have long been considered intractable and untreatable. Psychedelics are going mainstream and are poised to create a revolution in mental health. Psychedelics have demonstrated their clinical efficacy in treating disorders that affect thousands of people. But while psychedelics are stepping into the limelight, there are still a number of hurdles to overcome including intellectual property protection and FDA/EMEA approval pathways.
Outsmarting Cancer: Next Generation Therapies
The past decades have brought us new oncology therapies including mAbs, vaccines, checkpoint inhibitors and there is still more on the horizon. Emerging directions include compounds that inhibit both CDK2 and CDK9, activate the immune system, among others as well as precision therapies. This discussion will focus on emerging and evolving directions in the development of novel therapeutics for difficult to treat cancers.
Beyond the COVID-19 Crisis: What We Learned in Record Time and How it Will Advance the Future
While there is no silver lining to a global pandemic that claimed millions of lives and disrupted every aspect of society, the response to COVID-19 has yielded remarkable progress and innovation in many areas that should be here to stay. Among them, telemedicine, intensified work on wearable and home-based technologies, the safe and effective use of data derived from these and other sources, and a new look at our critical supply chain. Leaders in the field of biotechnology, pandemic prevention and response, and innovative clinical delivery will share perspectives on what should be adopted to ensure effective control of COVID-19 and to enhance healthcare.
The Biden Policy: Will its Impact on the Biopharma Sector be a Net Gain or Loss?
It’s no secret that the biopharma industry is facing headwinds, in particular with regard to drug pricing. But, will Build Back Better be all bad? Perhaps not.
The 2022 program will feature insights from top investors and biopharma executives by:
- Examining how the biopharma industry can accelerate drug discovery and manufacturing to prepare for future pandemics.
Providing updates in hot therapeutic areas such as oncology, CNS, cell and gene therapy, rare disease.
Exploring how COVID-19 accelerated the adoption of all things digital through the Digital Medicine & Medtech Showcase program.
Showcasing the promise of early-stage innovation through the Seed Showcase program.
2022 Program Advisory Board
THE BIOTECH SHOWCASE FAMILY OF EVENTS
Your Biotech Showcase registration showcase registration gives you access Biotech Showcase, Digital Medicine and Medtech Showcase and Seed Showcase content. China Showcase is a separate registration.
2021 Program Highlights
Hours of session content
View these 2021 sessions
INVESTING IN DIVERSITY
RARE BEYOND THE SQUARE
From de-risking to value creation – The evolving role of patient communities in rare disease drug development and commercialization